Abstract:The use of reverse transcription-PCR (RT-PCR) to analyze cells in the blood of cancer patients for the detection of mRNA expressed in tumor cells has implications for both the prognosis and the monitoring of cancer patients for the efficacy of established or experimental therapies. Carcinoembryonic antigen (CEA) is expressed on approximately 95% of colorectal, gastric, and pancreatic tumors, and on the majority of breast, non-small cell lung, and head and neck carcinomas. CEA shed in serum is useful as a marker in only approximately 50% of colorectal cancer patients and rarely is shed by some other carcinoma types. RT-PCR has been used previously to detect CEA mRNA in cells in the blood and lymph nodes of cancer patients. Under the assay conditions validated in the studies reported here, 34 of 51 (67%) patients with different stages of colorectal cancer had blood cells that were positive by RT-PCR for CEA mRNA, whereas none of 18 patients with colonic polyps were positive; 2 of 60 apparently healthy individuals (who were age and sex matched with the carcinoma patients and were part of a colon cancer screening program as controls) were marginally positive. The results of CEA PCR in the blood of the carcinoma patients and the other groups showed strong statistical correlation with the disease (P2 < 0.0001). Analyses were carried out to detect both serum CEA protein levels and CEA mRNA in blood cells of colorectal carcinoma patients by RT-PCR. For all stages of disease, 18 of 51 patients (35%) were positive for serum CEA, whereas 35 of 51 (69%) were positive by RT-PCR. More importantly, only 5 of 23 (20%) of stage B and C colorectal cancer patients were positive for serum CEA, whereas 16 of 23 (70%) were positive by RT-PCR. The use of two other serum markers (CA19.9 and CA72-4) for colorectal cancer in combination with serum CEA scored two additional patients as positive; both were positive by RT-PCR for CEA mRNA. Pilot long-term longitudinal studies conducted before and after surgery identified some patients with CEA mRNA in blood cells that were negative for all serum markers, who eventually developed clinical metastatic disease. The studies reported here are the first to correlate RT-PCR results for CEA mRNA in blood cells with one or more serum markers for patients with different stages of colorectal cancer, and are the first long-term longitudinal studies to use RT-PCR to detect CEA mRNA in blood cells of cancer patients. Larger cohorts will be required in future studies to define the impact, if any, of this technology on prognosis and/or disease monitoring.

Quantitative Detection of Disseminated Cancer Cells in Peritoneal Washes with Real-Time RT-PCR for Patients with Colorectal Carcinoma and Its Clinical Significance

Quantitative detection of CEA level in the peritoneal cavity of colorectal carcinoma patients with real-time RT-PCR and Its clinical significance

Quantitative Real-Time RT-PCR Detection for CEA, CK20 and CK19 Mrna in Peripheral Blood of Colorectal Cancer Patients.

Detection of micrometastatic cancer cells in peritoneal cavity of patients with colorectal cancer

Clinical significance of CEA and CK20 expression in exfoliated cells by fiberoptic bronchoscopy brushing

THE EXPRESSION AND CLINICAL SIGNIFICANCE OF CYTOKERATIN 20 mRNA IN CENTRAL VEIN BLOOD OF PATIENTS WITH GASTRIC CANCER BY RT-PCR

[Clinical significance of CEA mRNA detection in pleural and peritoneal effusions by real-time fluorescent quantitative RT-PCR].

The Use of CellCollector Assay to Detect Free Cancer Cells in the Peritoneal Cavity of Colorectal Cancer Patients: An Experimental Study

Significance of CK20 Mrna Expression in Peripheral Blood of Colorectal Cancer Patients by Real-Time Fluorescent Quantitative RT-PCR

Dissemination Profile of Perioperative Tumor Cells in Peripheral Blood of Colorectal Cancer Patients Detected by Multiple Marker Genes

[Detection of CK19 and CEA mRNA expression for the diagnosis of peripheral blood micrometastases in patients with non-small cell lung cancer].

Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers

Molecular Detection of Disseminated Tumor Cells in the Peripheral Blood of Patients with Gastric Cancer: Evaluation of Their Prognostic Significance

Multipoint Quantification of Multimarker Genes in Peripheral Blood and Micrometastasis Characteristic in Peri-Operative Esophageal Cancer Patients

Diagnostic Potential Of Serum Exosomal Colorectal Neoplasia Differentially Expressed Long Non-Coding Rna (Crnde-P) And Microrna-217 Expression In Colorectal Carcinoma

Circulating tumor cell enumeration for improved screening and disease detection of patients with colorectal cancer

Synergistic diagnostic value of circulating tumor cells and tumor markers CEA/CA19-9 in colorectal cancer

[Combined Detection of CEA Mrna and CK 19 Mrna in Peripheral Blood Cells of Patients with Lung Cancer].

Detection of Micrometastasis in the Bone Marrow of Patients with Esophageal Carcinomas and Its Clinical Implications

The Diagnostic Significance of the Detection of Cytokeratin 19 Mrna by Quantitative RT-PCR in Benign and Malignant Pleural Effusions

Improved real-time rt-PCR assays of two colorectal cancer peripheral blood mRNA biomarkers: a pilot study.